Taxotere/Temodar/Cisplatin Study in Melanoma Patients
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
1. To determine the maximum tolerated dose of chemotherapy using Taxotere, Temodar, Cisplatin
(TTC) in patients with metastatic melanoma.
Secondary Objectives:
1. To determine the toxicity of chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in
patients with metastatic melanoma
2. To determine the response rate of induction chemotherapy using Taxotere, Temodar,
Cisplatin (TTC) in patients with metastatic melanoma.